As filed with the Securities and Exchange Commission on May 22, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Viking Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
46-1073877 |
(State or other jurisdiction of incorporation or organization) |
|
(I.R.S. Employer Identification No.) |
9920 Pacific Heights Blvd, Suite 350
San Diego, CA 92121
(Address of Principal Executive Offices) (Zip Code)
2024 Equity Incentive Plan
2024 Employee Stock Purchase Plan
(Full titles of the plans)
Brian Lian, Ph.D.
President and Chief Executive Officer
Viking Therapeutics, Inc.
9920 Pacific Heights Blvd, Suite 350
San Diego, CA 92121
(858) 704-4660
(Name, address and telephone number, including area code, of agent for service)
Copies to:
Jeffrey T. Hartlin, Esq.
Paul Hastings LLP
1117 S. California Avenue
Palo Alto, California 94304
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☑ |
|
|
Accelerated filer |
Non-accelerated filer |
|
|
Smaller reporting company |
|
|
|
Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
REGISTRATION OF ADDITIONAL SECURITIES
Viking Therapeutics, Inc. (the “Registrant”) has prepared this registration statement (this “Registration Statement”) in accordance with the requirements of Form S-8 under the Securities Act of 1933, as amended (the “Securities Act”), to register: (1) 12,000,000 shares of the Registrant’s common stock, $0.00001 par value per share (“Common Stock”), reserved for issuance under the Viking Therapeutics, Inc. 2024 Equity Incentive Plan (the “2024 Plan”); (2) 5,500,000 shares of Common Stock reserved for issuance under the Viking Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the “2024 ESPP”). On May 21, 2024, the stockholders of the Registrant approved the 2024 Plan and the 2024 ESPP, which supersede and replace the Viking Therapeutics, Inc. 2014 Equity Incentive Plan (the "2014 Plan") and 2014 Employee Stock Purchase Plan (the “2014 ESPP”), respectively, and no further awards or purchase rights will be granted under 2014 Plan or 2014 ESPP.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
The document(s) containing the information specified in Part I will be sent or given to employees as specified by Rule 428(b)(1) of the Securities Act. Such documents are not being filed with the Securities and Exchange Commission (the “Commission”) either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. Such documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II hereof, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.
The following documents filed by the Registrant with the Commission are hereby incorporated by reference into this Registration Statement:
|
(a) |
The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the Commission on February 7, 2024; |
|
(b) |
The Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 filed with the Commission on April 25, 2024; |
|
(c) |
The information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 from the Registrant’s revised definitive proxy statement on Schedule 14A, filed with the SEC on April 5, 2024; |
|
(d) |
The Registrant’s Current Reports on Form 8-K filed with the SEC on March 1, 2024 and March 4, 2024; and |
|
(e) |
The description of the Registrant’s common stock set forth in the Registration Statement on Form 8-A filed with the Commission on April 23, 2015 (File No. 001-37355) pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendments or reports filed for the purpose of updating such description, including the description of common stock contained in Exhibit 4.2 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on February 10, 2023. |
All other reports and other documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part of this Registration Statement from the date of the filing of such reports and documents, except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under Items 2.02 or 7.01 of Form 8-K that is not deemed filed under such provisions.
For the purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
You should rely only on the information provided or incorporated by reference in this Registration Statement or any related prospectus. The Registrant has not authorized anyone to provide you with different information. You should not assume that the information in this Registration Statement or any related prospectus is accurate as of any date other than the date on the front of the document.
You may contact the Registrant in writing or orally to request copies of the above-referenced filings, without charge (excluding exhibits to such documents unless such exhibits are specifically incorporated by reference into the information incorporated into this Registration Statement). Requests for such information should be directed to:
Viking Therapeutics, Inc.
9920 Pacific Heights Blvd, Suite 350
San Diego, CA 92121
(858) 704-4660
Attn: Chief Executive Officer
ITEM 4. DESCRIPTION OF SECURITIES.
Not applicable
ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL.
Not applicable
ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS.
Section 145 of the General Corporation Law of the State of Delaware, or the DGCL, authorizes a corporation’s board of directors to grant, and authorizes a court to award, indemnity to officers, directors and other corporate agents.
As permitted by Section 102(b)(7) of the DGCL, the Registrant’s amended and restated certificate of incorporation and amended and restated bylaws contain provisions that limit the liability of the Registrant’s directors for monetary damages to the fullest extent permitted by Delaware law. Consequently, the Registrant’s directors are not personally liable to the Registrant or the Registrant’s stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for the following:
Any amendment to, or repeal of, these provisions will not eliminate or reduce the effect of these provisions in respect of any act, omission or claim that occurred or arose prior to that amendment or repeal. If the DGCL is amended to provide for further limitations on the personal liability of directors of corporations, then the personal liability of the Registrant’s directors will be further limited to the greatest extent permitted by the DGCL.
The Registrant’s amended and restated certificate of incorporation provides that the Registrant will, under certain circumstances, indemnify any director, officer, employee or agent of the Registrant, subject to any provisions contained in the Registrant’s amended and restated bylaws. The Registrant’s amended and restated bylaws provide that the Registrant will indemnify, to the fullest extent permitted by law, each person who was or is made a party or is threatened to be made a party to, or is otherwise involved in, any action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was a director or officer of the Registrant, or is or was serving at the request of the
Registrant, as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against all expense, liability and loss (including, among other things, attorney’s fees and amounts paid in settlement) reasonably incurred or suffered by such director, officer, employee or agent in connection therewith, subject to certain conditions. The Registrant’s amended and restated bylaws also provide the Registrant with the power to, to the extent authorized by the Registrant’s board of directors, grant rights to indemnification and to advancement of expenses to any employee or agent of the Registrant to the fullest extent indemnification may be granted to the Registrant’s directors and officers. In addition, the Registrant’s amended and restated bylaws provide that the Registrant must advance expenses incurred by or on behalf of a director or officer in advance of the final disposition of any action or proceeding, subject to certain exceptions.
The Registrant has entered into separate indemnification agreements with each of its directors and executive officers that may be broader than the specific indemnification provisions contained in the DGCL. These indemnification agreements require the Registrant, among other things, to indemnify its directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require the Registrant to advance all expenses incurred by the directors and executive officers in investigating or defending any such action, suit or proceeding, subject to certain exceptions. The Registrant believes that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers. The limitation of liability and indemnification provisions that are included in the Registrant’s amended and restated certificate of incorporation, amended and restated bylaws and indemnification agreements with its directors and executive officers may discourage stockholders from bringing a lawsuit against the Registrant’s directors and executive officers for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against the Registrant’s directors and executive officers even though an action, if successful, might benefit the Registrant and other stockholders. Further, a stockholder’s investment may be adversely affected to the extent that the Registrant pays the costs of settlement and damage awards against directors and executive officers as required by these indemnification provisions. At present, the Registrant is not aware of any pending litigation or proceeding involving any person who is or was one of its directors, officers, employees or other agents or is or was serving at its request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, for which indemnification is sought, and the Registrant is not aware of any threatened litigation that may result in claims for indemnification.
The Registrant’s amended and restated bylaws provide that the Registrant may purchase and maintain insurance, at its expense, to protect itself and any person who is or was a director, officer, employee or agent of the Registrant or is or was serving at its request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss, whether or not the Registrant would have the power to indemnify such person against such expense, liability or loss under the DGCL. The Registrant maintains insurance under which, subject to the limitations of the insurance policies, coverage is provided to the Registrant’s directors and executive officers against loss arising from claims made by reason of breach of fiduciary duty or other wrongful acts as a director or executive officer, including claims relating to public securities matters, and to the Registrant with respect to payments that may be made by the Registrant to these directors and executive officers pursuant to the Registrant’s indemnification obligations or otherwise as a matter of law.
ITEM 8. EXHIBITS.
Exhibit Number |
|
Description |
|
|
|
3.1 |
|
|
|
|
|
3.2 |
|
|
|
|
|
4.1 |
|
|
|
|
|
4.2* |
|
Viking Therapeutics, Inc. 2024 Equity Incentive Plan. |
|
|
|
4.3* |
|
Form of Stock Option Award Agreement under the Viking Therapeutics, Inc. 2024 Equity Incentive Plan. |
|
|
|
4.4* |
|
Form of Restricted Stock Unit Award Agreement under the Viking Therapeutics, Inc. 2024 Equity Incentive Plan. |
|
|
|
4.5* |
|
Form of Restricted Stock Award Agreement under the Viking Therapeutics, Inc. 2024 Equity Incentive Plan. |
|
|
|
4.6* |
|
2024 Employee Stock Purchase Plan. |
|
|
|
5.1* |
|
|
|
|
|
23.1* |
|
Consent of Marcum LLP, Independent Registered Public Accounting Firm. |
|
|
|
23.2* |
|
Consent of Paul Hastings LLP is contained in Exhibit 5.1 to this Registration Statement. |
|
|
|
24.1* |
|
|
|
|
|
107* |
|
*Filed herewith.
ITEM 9. UNDERTAKINGS.
(a) The Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and
(iii) To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;
Provided, however, that:
(A) paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.
(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(b) The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating
to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(h) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on May 22, 2024.
|
Viking Therapeutics, Inc. |
||
|
|
|
|
|
By: |
/s/ Brian Lian, Ph.D. |
|
|
Name: |
Brian Lian, Ph.D. |
|
|
Title: |
President and Chief Executive Officer |
POWER OF ATTORNEY
Know All Persons By These Presents, that each person whose signature appears below constitutes and appoints Brian Lian, Ph.D. and Greg Zante, and each or any one of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
SIGNATURE |
|
TITLE |
|
DATE |
|
|
|
|
|
/s/ Brian Lian, Ph.D. |
|
|
|
|
Brian Lian, Ph.D. |
|
President, Chief Executive Officer and Director |
|
May 22, 2024 |
|
|
(Principal Executive Officer) |
|
|
/s/ Greg Zante |
|
|
|
|
Greg Zante |
|
Chief Financial Officer |
|
May 22, 2024 |
|
|
(Principal Financial and Accounting Officer) |
|
|
/s/ Matthew W. Foehr |
|
|
|
|
Matthew W. Foehr |
|
Director |
|
May 22, 2024 |
|
|
|
|
|
/s/ Lawson Macartney, Ph.D. |
|
|
|
|
Lawson Macartney, Ph.D. |
|
Director |
|
May 22, 2024 |
|
|
|
|
|
/s/ Sarah Kathryn Rouan |
|
|
|
|
Sarah Kathryn Rouan |
|
Director |
|
May 22, 2024 |
|
|
|
|
|
/s/ Charles A. Rowland Jr. |
|
|
|
|
Charles A. Rowland Jr. |
|
Director |
|
May 22, 2024 |
|
|
|
|
|
/s/ J. Matthew Singleton |
|
|
|
|
J. Matthew Singleton |
|
Director |
|
May 22, 2024 |
|
|
|
|
|
Exhibit 4.2
Viking Therapeutics, Inc.
2024 Equity Incentive Plan
Adopted by the Board of Directors: March 15, 2024
Approved by the Stockholders: May 21, 2024
Each Option and SAR will have such terms and conditions as determined by the Board. Each Option will be designated in writing as an Incentive Stock Option or Nonstatutory Stock Option at the time of grant; provided, however, that if an Option is not so designated or if an Option designated as an Incentive Stock Option fails to qualify as an Incentive Stock Option, then such Option will be a Nonstatutory Stock Option, and the shares purchased upon exercise of each type of Option will be separately accounted for. Each SAR will be denominated in shares of Common Stock equivalents. The terms and conditions of separate Options and SARs need not be identical; provided, however,
2
that each Award Agreement will conform (through incorporation of provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions:
3
Following the date of such termination, to the extent the Participant does not exercise such Award within the applicable Post-Termination Exercise Period (or, if earlier, prior to the expiration of the maximum term of such Award), such unexercised portion of the Award will terminate, and the Participant will have no further right, title or interest in
4
terminated Award, the shares of Common Stock subject to the terminated Award, or any consideration in respect of the terminated Award.
5
6
7
8
9
10
11
12
13
If all or any part of the Plan or any Award Agreement is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of the Plan or such Award Agreement not declared to be unlawful or invalid. Any Section of the Plan or any Award Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.
The Board may suspend or terminate the Plan at any time. No Incentive Stock Options may be granted after the tenth anniversary of the earlier of: (i) the Adoption Date, or (ii) the date the Plan is approved by the Company’s stockholders. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated.
14
As used in the Plan, the following definitions apply to the capitalized terms indicated below:
15
16
Notwithstanding the foregoing or any other provision of this Plan, (A) the term Change in Control shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, and (B) the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply.
17
18
19
20
21
[Remainder of Page Intentionally Left Blank]
22
Exhibit 4.3
Viking Therapeutics, Inc.
Stock Option Grant Notice
(2024 Equity Incentive Plan)
Viking Therapeutics, Inc. (the “Company”), pursuant to its 2024 Equity Incentive Plan (the “Plan”), has granted to you (“Optionholder”) an option to purchase the number of shares of Common Stock set forth below (the “Option”). Your Option is subject to all of the terms and conditions as set forth herein and in the Plan and the Stock Option Agreement, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein, but defined in the Plan or the Stock Option Agreement, shall have the meanings set forth in the Plan or the Stock Option Agreement, as applicable.
Optionholder: [ ]
Date of Grant: [ ]
Vesting Commencement Date: [ ]
Number of Shares of Common Stock Subject to Option: [ ]
Exercise Price (Per Share): [ ]
Total Exercise Price: [ ]
Expiration Date: [ ]
Type of Grant: [Incentive Stock Option] OR [Nonstatutory Stock Option]
Exercise and
Vesting Schedule: The Option will vest as follows:
[Twenty-five percent (25%) of the shares of Common Stock subject to the Option will vest on each one (1) year anniversary of the Vesting Commencement Date, , subject to the Optionholder’s Continuous Service through each applicable vesting date.].
Notwithstanding the foregoing, vesting shall terminate upon the Optionholder’s termination of Continuous Service.
Optionholder Acknowledgements: By your signature below, or by electronic acceptance or authentication in a form authorized by the Company, you understand and agree that:
Viking Therapeutics, Inc. |
Optionholder: |
By: |
____________________________________________ |
Signature |
Signature |
Title: |
Date: |
Date: |
|
Viking Therapeutics, Inc.
2024 Equity Incentive Plan
Stock Option Agreement
As reflected by your Stock Option Grant Notice (“Grant Notice”) Viking Therapeutics, Inc., (the “Company”) has granted you an option under its 2024 Equity Incentive Plan (the “Plan”) to purchase a number of shares of Common Stock at the exercise price indicated in your Grant Notice (the “Option”). Capitalized terms not explicitly defined in this Agreement, but defined in the Grant Notice or the Plan, shall have the meanings set forth in the Grant Notice or Plan, as applicable. The terms of your Option as specified in the Grant Notice and this Stock Option Agreement constitute your Option Agreement.
The general terms and conditions applicable to your Option are as follows:
1
Additionally, the Post-Termination Exercise Period of your Option may be extended as provided in the Plan.
To obtain the federal income tax advantages associated with an Incentive Stock Option, the Code requires that at all times beginning on the date of grant of your Option, and ending on the day three months before the date of your Option’s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or Disability. If the Company provides for the extended exercisability of your Option under certain circumstances for your benefit, your Option will not necessarily be treated as an Incentive Stock Option if you exercise your Option more than three months after the date your employment terminates.
2
3
* * * *
4
Exhibit 4.4
Viking Therapeutics, Inc.
RSU Award Grant Notice
(2024 Equity Incentive Plan)
Viking Therapeutics, Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company’s 2024 Equity Incentive Plan (the “Plan”) and the Award Agreement (the “Agreement”), which are incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Agreement shall have the meanings set forth in the Plan or the Agreement.
Participant: [ ]
Date of Grant: [ ]
Vesting Commencement Date: [ ]
Number of Restricted Stock Units: [ ]
Vesting Schedule: The RSU Award will vest as follows:
[Twenty-five percent (25%) of the restricted stock units subject to the RSU Award will vest on each one (1) year anniversary of the Vesting Commencement Date, subject to the Participant’s Continuous Service through each applicable vesting date.]
Notwithstanding the foregoing, vesting shall terminate upon the Participant’s termination of Continuous Service.
Issuance Schedule: One share of Common Stock will be issued for each restricted stock unit, which vests at the time set forth in Section 5 of the Agreement.
Participant Acknowledgements: By your signature below or by electronic acceptance or authentication in a form authorized by the Company, you understand and agree that:
Viking Therapeutics, Inc. |
Participant: |
By: |
____________________________________________ |
Signature |
Signature |
Title: |
Date: |
Date: |
|
Viking Therapeutics, Inc.
2024 Equity Incentive Plan
Award Agreement (RSU Award)
As reflected by your Restricted Stock Unit Grant Notice (“Grant Notice”), Viking Therapeutics, Inc. (the “Company”) has granted you an RSU Award under its 2024 Equity Incentive Plan (the “Plan”) for the number of restricted stock units as indicated in your Grant Notice (the “RSU Award”). The terms of your RSU Award as specified in this Award Agreement for your RSU Award (the “Agreement”) and the Grant Notice constitute your “RSU Award Agreement”. Defined terms not explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall have the same definitions as in the Grant Notice or Plan, as applicable.
The general terms applicable to your RSU Award are as follows:
1
2
3
Exhibit 4.5
Viking Therapeutics, Inc.
Restricted Stock Award Grant Notice
(2024 Equity Incentive Plan)
Viking Therapeutics, Inc. (the “Company”) has awarded to you (the “Participant”) the number of shares of Common Stock on the terms set forth below in consideration of your services (the “Restricted Stock”). The grant of the Restricted Stock (the “Restricted Stock Award”) is subject to all of the terms and conditions as set forth herein and in the Company’s 2024 Equity Incentive Plan (the “Plan”) and the Award Agreement (the “Agreement”), which are incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Agreement shall have the meanings set forth in the Plan or the Agreement.
Participant:
Date of Grant:
Vesting Commencement Date:
Number of Shares of Restricted Stock:
Vesting Schedule: The Restricted Stock Award will vest as follows:
[Twenty-five percent (25%) of the shares of Common Stock subject to the Restricted Stock Award will vest on each one (1) year anniversary of the Vesting Commencement Date, subject to the Participant’s Continuous Service through each applicable vesting date.]
Notwithstanding the foregoing, vesting shall terminate upon the Participant’s termination of Continuous Service.
Participant Acknowledgements: By your signature below or by electronic acceptance or authentication in a form authorized by the Company, you understand and agree that:
Viking Therapeutics, Inc. |
Participant: |
By: |
____________________________________________ |
Signature |
Signature |
Title: |
Date: |
Date: |
|
Viking Therapeutics, Inc.
2024 Equity Incentive Plan
Award Agreement (Restricted Stock Award)
As reflected by your Restricted Stock Award Grant Notice (“Grant Notice”), Viking Therapeutics, Inc. (the “Company”) has granted you a number of shares of Restricted Stock under its 2024 Equity Incentive Plan (the “Plan”) as indicated in your Grant Notice (the “Restricted Stock Award”). The terms of your Restricted Stock Award as specified in this Award Agreement for your Restricted Stock Award (the “Agreement”) and the Grant Notice constitute your “Restricted Stock Award Agreement”. Defined terms not explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall have the same definitions as in the Grant Notice or the Plan, as applicable.
The general terms applicable to your Restricted Stock Award are as follows:
1
2
3
Exhibit 4.6
Viking Therapeutics, Inc.
2024 Employee Stock Purchase Plan
Adopted by the Board Of Directors: March 15, 2024
Approved by the Stockholders: May 21, 2024
2
3
4
5
The Company will seek to obtain from each U.S. federal or state, foreign or other regulatory commission, agency or other Governmental Body having jurisdiction over the Plan, such authority as may be required to grant Purchase Rights and issue and sell shares of Common Stock thereunder unless the Company determines, in its sole discretion, that doing so is not practical or would cause the Company to incur costs that are unreasonable. If, after commercially reasonable efforts, the Company is unable to obtain the authority that counsel for the Company deems necessary for the grant of Purchase Rights or the lawful issuance and sale of Common Stock under the Plan, and at a commercially reasonable cost, the Company will be relieved from any liability for failure to grant Purchase Rights and/or to issue and sell Common Stock upon exercise of such Purchase Rights.
6
Any benefits, privileges, entitlements and obligations under any outstanding Purchase Rights granted before an amendment, suspension or termination of the Plan will not be materially impaired by any such amendment, suspension or termination except (i) with the consent of the person to whom such Purchase Rights were granted, (ii) as necessary to facilitate compliance with any laws, listing requirements, or governmental regulations (including, without limitation, the provisions of Section 423 of the Code and the regulations and other interpretive guidance issued thereunder relating to Employee Stock Purchase Plans) including without limitation any such regulations or other guidance that may be issued or amended after the date the Plan is adopted by the Board, or (iii) as necessary to obtain or maintain favorable tax, listing, or regulatory treatment. To be clear, the Board may amend outstanding Purchase Rights without a Participant’s consent if such amendment is necessary to ensure that the Purchase Right and/or the Plan complies with the requirements of Section 423 of the Code with respect to the 423 Component or with respect to other Applicable Laws. Notwithstanding anything in the Plan or any Offering Document to the contrary, the Board will be entitled to: (i) establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars; (ii) permit Contributions in excess of the amount designated by a Participant in order to adjust for mistakes in the Company’s processing of properly completed Contribution elections; (iii) establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the purchase of Common Stock for each Participant properly correspond with amounts withheld from the Participant’s Contributions; (iv) amend any outstanding Purchase Rights or clarify any ambiguities regarding the terms of any Offering to enable the Purchase Rights to qualify under and/or comply with Section 423 of the Code with respect to the 423 Component; and (v) establish other limitations or procedures as the Board determines in its sole discretion advisable that are consistent with the Plan. The actions of the Board pursuant to this paragraph will not be considered to alter or impair any Purchase Rights granted under an Offering as they are part of the initial terms of each Offering and the Purchase Rights granted under each Offering.
7
The Plan will become effective on the date on which the Company’s stockholders approve the adoption of the Plan. No Purchase Rights will be exercised unless and until the Plan has been approved by the stockholders of the Company, which approval must be within 12 months before or after the date the Plan is adopted (or if required under Section 12(a) above, materially amended) by the Board.
8
As used in the Plan, the following definitions will apply to the capitalized terms indicated below:
9
10
[Remainder of Page Intentionally Left Blank]
11
Exhibit 5.1
79891.00006
May 22, 2024
Viking Therapeutics, Inc.
9920 Pacific Heights Blvd, Suite 350
San Diego, CA 92121
Re: Registration Statement on Form S-8
Ladies and Gentlemen:
We have acted as counsel to Viking Therapeutics, Inc., a Delaware corporation (the “Company”), in connection with the registration statement on Form S-8 to be filed by the Company with the U.S. Securities and Exchange Commission (the “Commission”) on or about the date hereof (the “Registration Statement”) to effect registration under the Securities Act of 1933, as amended (the “Securities Act”), of an aggregate of up to 17,500,000 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (“Common Stock”), comprised of: (i) 12,000,000 shares of Common Stock issuable upon the vesting and/or exercise of awards to be granted by the Company pursuant to the Company’s 2024 Equity Incentive Plan (the “2024 Equity Plan”); and (ii) 5,500,000 shares of Common Stock issuable upon the exercise of purchase rights to be granted by the Company pursuant to the Company’s 2024 Employee Stock Purchase Plan (the “2024 ESPP” and, together with the 2024 Equity Plan, the “Plans”).
As such counsel and for purposes of our opinion set forth below, we have examined and relied upon originals or copies, certified or otherwise identified to our satisfaction, of such documents, resolutions, certificates and instruments of the Company and corporate records furnished to us by the Company, and have reviewed certificates of public officials, statutes, records and such other instruments and documents as we have deemed necessary or appropriate as a basis for the opinion set forth below, including, without limitation:
Viking Therapeutics, Inc.
May 22, 2024
Page 2
In addition to the foregoing, we have made such investigations of law as we have deemed necessary or appropriate as a basis for the opinion set forth in this opinion letter.
In such examination and in rendering the opinion expressed below, we have assumed, without independent investigation or verification: (i) the genuineness of all signatures on all agreements, instruments, corporate records, certificates and other documents submitted to us; (ii) the authenticity and completeness of all agreements, instruments, corporate records, certificates and other documents submitted to us as originals; (iii) that all agreements, instruments, corporate records, certificates and other documents submitted to us as certified, electronic, facsimile, conformed, photostatic or other copies conform to originals thereof, and that such originals are authentic and complete; (iv) the legal capacity and authority of all persons or entities (other than the Company) executing all agreements, instruments, corporate records, certificates and other documents submitted to us; (v) the due authorization, execution and delivery of all agreements, instruments, corporate records, certificates and other documents by all parties thereto (other than the Company); (vi) that no documents submitted to us have been amended or terminated orally or in writing except as has been disclosed to us in writing; (vii) that the statements contained in the certificates and comparable documents of public officials, officers and representatives of the Company and other persons on which we have relied for the purposes of this opinion letter are true and correct; (viii) that there has not been any change in the good standing status of the Company from that reported in the Good Standing Certificate; and (ix) that each of the officers and directors of the Company has properly exercised his or her fiduciary duties. As to all questions of fact material to this opinion letter, and as to the materiality of any fact or other matter referred to herein, we have relied (without independent investigation or verification) upon representations and certificates or comparable documents of officers and representatives of the Company. Our knowledge of the Company and its legal and other affairs is limited by the scope of our engagement, which scope includes the delivery of this opinion letter. We do not represent the Company with respect to all legal matters or issues. The Company may employ other independent counsel and, to our knowledge, handles certain legal matters and issues without the assistance of independent counsel. We have also assumed that the individual issuances, grants, awards or grants of purchase rights under the Plans will be duly authorized by all necessary corporate action of the Company and duly issued, granted or awarded and exercised in accordance with the requirements of law, the Plans and the agreements, forms of instrument, awards and grants duly adopted thereunder.
Based upon the foregoing, and in reliance thereon, and subject to the assumptions, limitations, qualifications and exceptions set forth herein, we are of the opinion that the Shares are duly authorized and, when issued and sold as described in the Registration Statement and in accordance with the Plans and the applicable award agreements or forms of instrument evidencing purchase rights thereunder (including the receipt by the Company of the full consideration therefor), will be validly issued, fully paid and nonassessable.
Without limiting any of the other limitations, exceptions and qualifications stated elsewhere herein, we express no opinion with regard to the applicability or effect of the laws of any jurisdiction other than the General Corporation Law of the State of Delaware, as in effect on the date of this opinion letter.
This opinion letter deals only with the specified legal issues expressly addressed herein, and you should not infer any opinion that is not explicitly stated herein from any matter addressed in this opinion letter.
This opinion letter is rendered solely in connection with the issuance and delivery of the Shares as described in the Registration Statement and in accordance with the terms of the Plans and the applicable award agreement or form of instrument evidencing purchase rights thereunder. This opinion letter is rendered as of the date hereof, and we assume no obligation to advise you or any other person with regard to any change after the date hereof in the circumstances or the law that may bear on the matters set forth herein even if the change may affect the legal analysis or a legal conclusion or other matters in this opinion letter.
Viking Therapeutics, Inc.
May 22, 2024
Page 3
We hereby consent to the filing of this opinion letter as Exhibit 5.1 to the Registration Statement. In giving such consent, we do not hereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules or regulations of the Commission thereunder.
Very truly yours,
/s/ Paul Hastings LLP
Exhibit 23.1
Independent Registered Public Accounting Firm’s Consent
We consent to the incorporation by reference in this Registration Statement of Viking Therapeutics, Inc. on Form S-8 of our report dated February 7, 2024, with respect to our audits of the consolidated financial statements of Viking Therapeutics, Inc. as of December 31, 2023 and 2022 and for the years ended December 31, 2023 and 2022 and our report dated February 7, 2024 with respect to our audit of internal control over financial reporting of Viking Therapeutics, Inc. as of December 31, 2023 appearing in the Annual Report on Form 10-K of Viking Therapeutics, Inc. for the year ended December 31, 2023.
/s/ Marcum llp
Marcum llp
Costa Mesa, California
May 22, 2024
Exhibit 107
Calculation of Filing Fee Tables
Form S-8
(Form Type)
Viking Therapeutics, Inc.
(Exact name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
Security Type |
Security Class Title |
Fee Calculation Rule |
Amount Registered(1) |
Proposed Maximum Offering Price Per Unit |
Maximum Aggregate Offering Price |
Fee Rate |
Amount of Registration Fee |
Equity |
Common Stock, par value $0.00001 per share |
457(h) |
12,000,000 |
$65.63(2) |
$787,560,000.00 |
0.0001476 |
$116,243.86 |
Equity |
Common Stock, par value $0.00001 per share |
457(h) |
5,500,000 |
$55.7855(3) |
$306,820,250.00 |
0.0001476 |
$45,286.67 |
Total Offering Amounts |
$1,094,380,250.00 |
— |
$161,530.53 |
||||
Total Fee Offsets |
— |
— |
$5,162.08 |
||||
Net Fee Due |
— |
— |
$156,368.45 |
(1) |
Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s Common Stock (“Common Stock”) that become issuable under the Viking Therapeutics, Inc. 2024 Equity Incentive Plan (the “2024 Plan”) and the Viking Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the “2024 ESPP”) by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of Common Stock. |
(2) |
Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act. The proposed maximum offering price per share and the proposed maximum aggregate offering price with respect to the shares are calculated based on $65.63 per share, the average of the high and low prices of the Common Stock, as reported on the Nasdaq Capital Market on May 21, 2024, a date within five business days prior to the filing of this Registration Statement. |
(3) |
Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act. The proposed maximum aggregate offering price per share and the proposed maximum aggregate offering price with respect to these shares are calculated based on 85% of the average of the high and low prices of the Common Stock, as reported on the Nasdaq Capital Market on May 21, 2024, a date within five business days prior to the filing of this Registration Statement. Pursuant to the 2024 ESPP, the purchase price of the shares of Common Stock reserved for issuance thereunder will be the lower of (i) 85% of the fair market value per share of the Common Stock on the first day of the |
|
offering or (ii) 85% of the fair market value per share of the Common Stock on the date the purchase right is exercised, which will be the last day of the applicable purchase period. |
Table 2: Fee Offset Claims and Sources
|
Registrant or Filer Name |
Form or Filing Type |
File Number |
Initial Filing Date |
Filing Date |
Fee Offset Claimed |
Security Type Associated with Fee Offset Claimed |
Security Title Associated with Fee Offset Claimed |
Unsold Securities Associated with Fee Offset Claimed |
Unsold Aggregate Offering Amount Associated with Fee Offset Claimed |
Fee Paid with Fee Offset Source |
|
|
Rule 457(p) |
|||||||||||
File Offset Claims |
Viking Therapeutics, Inc. |
Form S-8 |
333-276939 |
2/7/24 |
|
$2,916.94 |
Equity(4) |
Common Stock, par value $0.00001 per share |
1,001,137 |
$19,762,444.38 |
|
|
File Offset Sources |
Viking Therapeutics, Inc. |
Form S-8 |
333-276939 |
|
2/7/24 |
|
|
|
|
|
$2,916.94 |
|
File Offset Claims |
Viking Therapeutics, Inc. |
Form S-8 |
333-269675 |
2/10/23 |
|
$679.57 |
Equity(4) |
Common Stock, par value $0.00001 per share |
782,572 |
$6,166,667.36 |
|
|
File Offset Sources |
Viking Therapeutics, Inc. |
Form S-8 |
333-269675 |
|
2/10/23 |
|
|
|
|
|
$679.57 |
|
File Offset Claims |
Viking Therapeutics, Inc. |
Form S-8 |
333-262609 |
2/9/22 |
|
$250.98 |
Equity(4) |
Common Stock, par value $0.00001 per share |
782,484 |
$2,707,394.64 |
|
|
File Offset Sources |
Viking Therapeutics, Inc. |
Form S-8 |
333-262609 |
|
2/9/22 |
|
|
|
|
|
$250.98 |
|
File Offset Claims |
Viking Therapeutics, Inc. |
Form S-8 |
333-253219 |
2/17/21 |
|
$682.96 |
Equity(4) |
Common Stock, par value $0.00001 per share |
732,159 |
$6,259,959.45 |
|
|
File Offset Sources |
Viking Therapeutics, Inc. |
Form S-8 |
333-253219 |
|
2/17/21 |
|
|
|
|
|
$682.96 |
|
File Offset Claims |
Viking Therapeutics, Inc. |
Form S-8 |
333-236666 |
2/26/20 |
|
$631.63 |
Equity(4) |
Common Stock, par value $0.00001 per share |
724,136 |
$4,866,193.92 |
|
|
File Offset Sources |
Viking Therapeutics, Inc. |
Form S-8 |
333-236666 |
|
2/26/20 |
|
|
|
|
|
$631.63 |
(4) |
Comprised solely of shares of Common Stock previously registered for future issuance under the Viking Therapeutics, Inc. 2014 Employee Stock Purchase Plan, as amended (the “2014 ESPP”), which shares of Common Stock remain unsold under the 2014 ESPP and the prior Registration Statements on Form S-8 identified in this Fee Offset Claims and Sources table. The 2024 ESPP superseded and replaced the 2014 Plan, and no further purchase rights will be granted under the 2014 ESPP and the offering of shares under the 2014 ESPP has terminated. |
=[=Q
M]!D_A7S'8:=>:I=K:V%K+ &*0.T0.-X!SC-;GCS6_[;\3SM&V;:V_<18Z$ \G\3G\,5N^&OAK
M'K.AP:A>7DUN\^61$0'Y.QY]>OTQ3$:/_"WH/^@-)_W_ !_\31_PMZ#_ * T
MG_?\?_$U+_PJ.P_Z"ES_ -^UH_X5'8?]!2Y_[]K2&>;:Y?V^J:U=7UM;FWCG
M?S#&6W88]>?